Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
Close
  • Menu
  • Setting

Recombinant Mouse Erythropoietin/EPO, Tag Free

Catalog No.
PM2026
Recombinant Mouse Erythropoietin (EPO)
Grouped product items
Size Price Stock Qty
10ug
Special Price $144.00 Regular Price $320.00
Please inquire
100ug
Special Price $481.50 Regular Price $1,070.00
Please inquire
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

No Related Posts

Background

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin [1]. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species [2, 3]. Glycosylation of EPO is required for biological activities in vivo [4]. Mature mouse EPO shares 95% amino acid sequence identity with rat EPO and 73%-82% with bovine, canine, equine, feline, human, ovine, and porcine EPO. Epo is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules [5]. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain [6-8]. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the (EPO receptor (EPOR))[8, 9]. EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells [7,8,10,11]. Ligand induced dimerization of EPOR triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation [1,12]. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha [1,6]. EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis [7,8,13].

Reference

[1]. Koury, M. J. (2005) Exp. Hematol. 33:1263.

[2]. Shoemaker, C.B. and L.D. Mitsock (1986) Mol. Cell. Biol 6:849.

[3]. Wen, D. et al. (1993) Blood 82:1507.

[4]. Tsuda E. et al. (1990) Eur. J. Biochem. 188:405.

[5]. Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.

[6]. Eckardt, K. U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35 Suppl. 3:13.

[7]. Sharples, E. J. et al. (2006) Curr. Opin. Pharmacol. 6:184.

[8]. Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.

[9]. Koury, M.J. and M.C. Bondurant (1990) Science 248:378.

[10]. Acs, G. et al. (2001) Cancer Res. 61:3561.

[11]. Hardee, M.E. et al. (2006) Clin. Cancer Res.

[12]:332. 12. Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.

[13]. Kertesz, N. et al. (2004) Dev. Biol. 276:101

Description

Accession #

Q0VED9

Alternate Names

ECYT5; EP; EPO; epoetin; Erythropoietin; MGC138142; MVCD2

Source

Human embryonic kidney cell, HEK293-derived mouse Erythropoietin/EPO protein

Protein sequence

Ala27-Arg192

M.Wt

18.6 kDa

Appearance

Solution protein

Stability & Storage

Avoid repeated freeze-thaw cycles. It is recommended that hat the protein be aliquoted for optimal storage.- 12 months from date of receipt, -20 to -70°C as supplied.

Concentration

0. 2 mg/mL

Formulation

Dissolved in sterile PBS buffer.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers.

Biological Activity

The EC50 for this effect is 0.1-0.4 ng/mL. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.

Shipping Condition

Shipping with dry ice.

Handling

Centrifuge the vial prior to opening.

Usage

For Research Use Only! Not to be used in humans.

Quality Control

Quality Control & DataSheet

View current batch:
    Purity > 95%, determined by SDS-PAGE.
    Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.
  • Datasheet